- Home
- PLUG vs ARQT Comparison
PLUG vs ARQT Comparison
Compare PLUG & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLUG | ARQT |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.5B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLUG | ARQT |
|---|---|---|
| Price | $2.15 | $23.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $2.31 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 54.0M | 1.7M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 47.01 | ★ 88.79 |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $709,919,000.00 | $376,072,000.00 |
| Revenue This Year | $26.67 | $34.85 |
| Revenue Next Year | $8.09 | $29.39 |
| P/E Ratio | ★ N/A | $794.67 |
| Revenue Growth | 12.90 | ★ 91.34 |
| 52 Week Low | $1.52 | $16.62 |
| 52 Week High | $4.58 | $31.77 |
Technical Indicators
Market Signals| Indicator | PLUG | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 37.18 |
| Support Level | $1.89 | $22.73 |
| Resistance Level | $2.50 | $23.46 |
| Average True Range (ATR) | 0.10 | 0.79 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 16.07 | 9.76 |
Price Performance
Historical ComparisonAbout PLUG Plug Power Inc.
Plug Power Inc is building an end-to-end green hydrogen ecosystem, from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.